1. Hammer S, Saag M, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827–43. [PubMed]
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Departments of Health and Human Services; Jan 29, 2008. pp. 1–128.
3. Deval J, Selmi B, Boretto J, et al. The molecular mechanism of multidrug resistance by the Q151M HIV-1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogs. J Biol Chem. 2002;277:42097–104. [PubMed] 4. Deval J, White K, Miller M, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem. 2004;279:509–16. [PubMed] 5. Arion D, Kaushik N, McCormick S, Borkow G, Parniak M. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyro-phosphate of the mutant viral reverse transcriptase. Biochemistry. 1998;37:15908–17. [PubMed] 6. Meyer P, Matsuura S, Mian A, So A, Scott W. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell. 1999;4:35–43. [PubMed] 7. Boyer P, Sarafianos S, Arnold E, Hughes S. Selective excision of AZTMP by drug-resistant HIV reverse transcriptase. J Virol. 2001;75:4832–42. [PMC free article] [PubMed] 8. Whitcomb J, Parkin N, Chappey C, Hellmann N, Petropoulos CJ. Broad NRTI cross-resistance in HIV-1 clinical isolates. J Infect Dis. 2003;188:992–1000. [PubMed] 9. Eron J. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS. 1996;10(Suppl 5):S11–19. [PubMed] 10. Ingrand D, Weber J, Boucher C, et al. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group. AIDS. 1995;9:1323–9. [PubMed] 11. Pluda J, Cooley T, Montaner J, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced HIV infection. J Infect Dis. 1995;171:1438–47. [PubMed] 12. Miller V, Stark T, Loeliger A, Lange J. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 2002;3:135–45. [PubMed] 13. Diallo K, Gotte M, Wainberg M. Molecular impact of the M184V mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother. 2003;47:3377–83. [PMC free article] [PubMed] 14. Vray M, Meynard J, Dalban C, et al. Predictors of the virologic response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotype and standard of care (Narval trial, ANRS 088) Antivir Ther. 2003;8:427–34. [PubMed] 15. Petropoulos C, Parkin N, Limoli K, et al. A novel phenotypic drug susceptibility assay for HIV-1. Antimicrob Agents Chemother. 2000;44:920–8. [PMC free article] [PubMed] 16. Rhee S, Liu T, Ravela J, Gonzales M, Shafer R. Distribution of HIV-1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother. 2004;48:3122–6. [PMC free article] [PubMed] 17. Brun-Vezinet F, Descamps D, Ruffault A, et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS. 2003;17:1795–802. [PubMed] 18. Winters M, Bosch R, Albrecht M, Katzenstein D. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in NRTI-experienced patients. J Infect Dis. 2003;188:537–40. [PubMed] 19. Lanier E, Ait-Khaled M, Scott J, et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harboring HIV-1 with specific patterns of resistance to NRTI. Antivir Ther. 2004;9:37–45. [PubMed] 20. Marcelin A, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother. 2005;49:1739–44. [PMC free article] [PubMed] 21. Molina J, Marcelin A, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191:8407. [PubMed] 22. Eron J, Bosch R, Bettendorf D, Petch L, Fiscus S, Frank I. The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J Acquir Immune Defic Syndr. 2007;45:249–51. [PubMed] 23. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods. 2007;145:47–55. [PubMed]
24. Bennett D, McCormick L, Kline R, et al. U.S. surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera. 12th CROI; Boston, USA. 2005. Abstract 674.
25. Fessel W, Rhee S, Klein D, et al. Low risk of initial antiretroviral treatment failure in patients with wild-type HIV-1 by standard genotypic resistance testing. 15th CROI; Boston, USA. 2008. abstract 892.
26. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease genes in HIV-1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol. 1999;37:4099–106. [PMC free article] [PubMed] 27. Gonzales M, Wu T, Taylor J, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS. 2003;17:791–9. [PMC free article] [PubMed] 28. Marcelin A, Delaugerre C, Wirden M, et al. Thymidine analog reverse transcriptase inhibitors resistance mutations profiles and association to other NRTI resistance mutations observed in the context of virologic failure. J Med Virol. 2004;72:162–5. [PubMed] 29. Miller M, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189:837–46. [PubMed] 30. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analog mutation profiles: factors associated with acquiring specific profiles and their impact on the virologic response to therapy. Antivir Ther. 2005;10:791–802. [PubMed] 31. De Luca A, Di Giambenedetto S, Romano L, et al. Frequency and treatment-related predictors of thymidine-analog mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. J Infect Dis. 2006;193:1219–22. [PubMed] 32. Rhee S, Liu T, Holmes S, Shafer R. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol. 2007;3:e87. [PubMed] 33. Yahi N, Tamalet C, Tourres C, Tivoli N, Fantini J. Mutation L210W of HIV-1 reverse transcriptase in patients receiving combination therapy; incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci. 2000;7:507–13. [PubMed] 34. Marcelin A, Flandre P, Furco A, Wirden M, Molina J, Calvez V. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virologic response to didanosine. Antivir Ther. 2006;11:693–9. [PubMed] 35. De Luca A, Giambenedetto S, Trotta M, et al. Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virologic response to didanosine. J Infect Dis. 2007;196:1645–53. [PubMed] 36. Yerly S, Rakik A, De Loes SK, et al. Switch to unusual amino acids at codon 215 of the HIV-1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol. 1998;72:3520–3. [PMC free article] [PubMed] 37. Garcia-Lerma J, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA. 2001;98:13907–12. [PubMed] 38. Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard J, Chaix M. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol. 2005;32:241–4. [PubMed] 39. Sluis-Cremer N, Sheen C, Zelina S, Argoti Torres P, Parikh U, Mellors J. Molecular mechanism by which K70E in HIV-1 reverse transcriptase confers resistance to NRTI. Antimicrob Agents Chemother. 2006;51:48–53. [PMC free article] [PubMed] 40. Bradshaw D, Malik S, Booth C, et al. Novel drug resistance pattern associated with the mutations K70G and M184V in HIV-1 reverse transcriptase. Antimicrob Agents Chemother. 2007;51:4489–91. [PMC free article] [PubMed] 41. Rhee S, Fessel W, Zolopa A, et al. HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005;192:456–65. [PMC free article] [PubMed] 42. Delaugerre C, Mouroux M, Yvon-Groussin A, et al. Prevalence and conditions of selection of E44D/A and V118I HIV-1 reverse transcriptase mutations in clinical practice. Antimicrob Agents Chemother. 2001;45:946–8. [PMC free article] [PubMed] 43. Montes B, Segondy M. Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase gene of HIV-1 in relation to treatment with nucleoside analog RT inhibitors. J Med Virol. 2002;66:299–303. [PubMed] 44. Hertogs K, Bloor S, De Vroey V, et al. A novel HIV-1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother. 2000;44:568–73. [PMC free article] [PubMed] 45. Perno C, Cozzi-Lepri A, Balotta C, et al. Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy. Antivir Ther. 2001;6:195–8. [PubMed] 46. Walter H, Schmidt B, Werwein M, Schwingel E, Korn K. Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother. 2002;46:89–94. [PMC free article] [PubMed] 47. Romano L, Venturi G, Bloor S, et al. Broad nucleoside-analog resistance implications for HIV-1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis. 2002;185:898–904. [PubMed] 48. Stoeckli T, MaWhinney S, Uy J, et al. Phenotypic and genotypic analysis of biologically cloned HIV-1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother. 2002;46:4000–3. [PMC free article] [PubMed] 49. Girouard M, Diallo K, Marchand B, McCormick S, Gotte M. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC. J Biol Chem. 2003;278:34403–10. [PubMed] 50. Saberg P, Koppel K, Bratt G, et al. The reverse transcriptase mutation V118I is associated with virologic failure on abacavir-based ART in HIV-1 infection. Scand J Infect Dis. 2004;36:40–5. [PubMed] 51. Gianotti N, Galli L, Boeri E, et al. The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2006;41:447–52. [PubMed] 52. Zaccarelli M, Tozzi V, Lorenzini P, et al. The V118I mutation as a marker of advanced HIV infection and disease progression. Antivir Ther. 2007;12:163–8. [PubMed] 53. Svicher V, Sing T, Santoro M, et al. Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol. 2006;80:7186–98. [PMC free article] [PubMed] 54. Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, et al. Impact of HIV-1 reverse transcriptase polymorphism F214L on virologic response to thymidine analog-based regimens in ART-naive and ART-experienced patients. J Infect Dis. 2007;196:1180–90. [PubMed] 55. Moyle G, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr. 2005;38:417–25. [PubMed] 56. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. [PubMed] 57. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476–82. [PubMed] 58. Lanier E, Givens N, Stone C, et al. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 2004;5:394–9. [PubMed] 59. Staszewski S, Dauer B, Locher L, Moesch M, Gute P, Stuermer M. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of the K65R Mutation. 13th CROI; 2006. abstract 635. [PubMed] 60. Antinori A, Trotta M, Lorenzini P, et al. Virologic response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation. Antivir Ther. 2007;12:1175–83. [PubMed] 61. Rhee S, Taylor J, Wadhera G, Ben-Hur A, Brutlag D, Shafer R. Genotypic predictors of HIV-1 drug resistance. Proc Natl Acad Sci USA. 2006;103:17355–60. [PubMed] 62. Wirden M, Roquebert B, Derache A, et al. Risk factors for selection of the L74I reverse transcriptase mutation in HIV-1-infected patients. Antimicrob Agents Chemother. 2006;50:2553–6. [PMC free article] [PubMed] 63. Berkhout B, Back N, de Ronde A, et al. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS. 2006;20:1515–20. [PubMed] 64. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of TDF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201. [PubMed] 65. Margot N, Lu B, Cheng A, Miller M. Resistance development over 144 weeks in treatment-naive patients receiving TDF or stavudine with lamivudine and efavirenz in Study 903. HIV Med. 2006;7:442–50. [PubMed] 66. Sosa N, Hill-Zabala C, Dejesus E, et al. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL) J Acquir Immune Defic Syndr. 2005;40:422–7. [PubMed] 67. Smith K, Weinberg W, Dejesus E, et al. AIDS Res Ther. Vol. 5. 2008. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT; p. 5. [PMC free article] [PubMed] 68. Saag M, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA. 2004;292:180–9. [PubMed] 69. Descamps D, Ait-Khalid M, Craig C, et al. Rare selection of the K65R mutation in antiretroviral naive patients failing a first-line abacavir/lamivudine-containing HAART regimen. Antivir Ther. 2006;11:701–5. [PubMed] 70. Svarovskaia E, Margot N, Bae A, et al. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. J Acquir Immune Defic Syndr. 2007;46:174–80. [PubMed] 71. Parikh U, Bacheler L, Koontz D, Mellors J. The K65R mutation in HIV-1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol. 2006;80:4971–7. [PMC free article] [PubMed] 72. Parikh U, Zelina S, Sluis-Cremer N, Mellors J. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS. 2007;21:1405–14. [PubMed] 73. Parikh U, Barnas D, Faruki H, Mellors J. Antagonism between the HIV-1 reverse transcriptase mutation K65R and thymidine-analog mutations at the genomic level. J Infect Dis. 2006;194:651–60. [PubMed] 74. Shafer R, Kozal M, Winters M, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant HIV-1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994;169:722–9. [PubMed] 75. Roge B, Katzenstein T, Obel N, et al. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther. 2003;8:173–82. [PubMed] 76. Shafer R, Smeaton LM, Robbins G, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304–15. [PubMed] 77. Rey D, Krebs M, Partisani M, et al. Virologic response of zidovudine, lamivudine, and TDF combination in antiretroviral-naive HIV-1-Infected Patients. J Acquir Immune Defic Syndr. 2006;43:530–4. [PubMed] 78. DART Virology Group and Trial Team. Virologic response to a triple nucleoside/nucleotide analog regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS. 2006;20:1391–9. [PubMed] 79. Masquelier B, Neau D, Boucher S, et al. Antiretroviral efficacy and virologic profile of a zidovudine/lamivudine/TDF combination therapy in antiretroviral-naive patients. Antivir Ther. 2006;11:827–30. [PubMed] 80. Elion R, Cohen C, Dejesus E, et al. Once-daily abacavir/lamivudine/zidovudine plus TDF for the treatment of HIV-1 infection in antiretroviralnaive subjects: a 48-week pilot study. HIV Clin Trials. 2006;7:324–33. [PubMed] 81. Sturmer M, Staszewski S, Doerr H. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther. 2007;12:695–703. [PubMed] 82. Ross L, Dretler R, Gerondelis P, Rouse E, Lim M, Lanier E. A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to TDF, lamivudine and didanosine. AIDS. 2006;20:787–9. [PubMed] 83. Bartlett J, Johnson J, Herrera G, et al. Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine. J Acquir Immune Defic Syndr. 2006;43:284–92. [PubMed]
84. Van Houtte M, Staes M, Geretti A, Patterry T, Bacheler L. NRTI resistance associated with the RT mutation K70E in HIV-1. Antivir Ther. 2006;11:S160. abstract 144.
85. Ross L, Gerondelis P, Liao Q, et al. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naive subjects treated with tenofovir/abacavir/lamivudine therapy. Antivir Ther. 2005;10:S102. abstract 92.
86. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in HIV-1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother. 1997;41:1094–8. [PMC free article] [PubMed] 87. Margot N, Miller M. In vitro combination studies of tenofovir and other nucleoside analogs with ribavirin against HIV-1. Antivir Ther. 2005;10:343–8. [PubMed] 88. Fitzgibbon J, Howell R, Haberzettl C, Sperber S, Gocke D, Dubin D. HIV-1 pol gene mutations which cause decreased susceptibility to 2′,3′dideoxycytidine. Antimicrob Agents Chemother. 1992;36:153–7. [PMC free article] [PubMed] 89. Lacey S, Larder B. Novel mutation (V75T) in HIV-1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 1994;38:1428–32. [PMC free article] [PubMed] 90. Winters M, Merigan T. Variants other than aspartic acid at codon 69 of the HIV-1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother. 2001;45:2276–9. [PMC free article] [PubMed] 91. Selmi B, Boretto J, Navarro J, et al. The valine-to-threonine 75 substitution in HIV-1 reverse transcriptase and its relation with stavudine resistance. J Biol Chem. 2001;276:13965–74. [PubMed] 92. Lennerstrand J, Stammers D, Larder B. Biochemical mechanism of HIV-1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother. 2001;45:2144–6. [PMC free article] [PubMed] 93. Brenner B, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9–13. [PubMed] 94. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in HIV-1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006;50:4182–5. [PMC free article] [PubMed]
95. Hawkins C, Chaplin B, Idoko J, et al. Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing stavudine, lamivudine, and nevirapine first line antiretroviral therapy. Antivir Ther. 2007;12:S78. abstract 69.
96. Rey D, Schmitt M, Hoizey G, et al. Early virologic non-response to once daily combination of lamivudine, tenofovir, and nevirapine n ART-naive HIV-infected patients: preliminary results of the DAUFIN study. 14th CROI; Los Angeles. 2007. abstract 503.
97. Winters M, Coolley K, Girard Y, et al. A 6-basepair insert in the reverse transcriptase gene of HIV-1 confers resistance to multiple nucleoside inhibitors. J Clin Invest. 1998;102:1769–75. [PMC free article] [PubMed] 98. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogs. Antimicrob Agents Chemother. 2000;44:2109–17. [PMC free article] [PubMed] 99. Masquelier B, Race E, Tamalet C, et al. Genotypic and phenotypic resistance patterns of HIV-1 variants with insertions or deletions in the RT: multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother. 2001;45:1836–42. [PMC free article] [PubMed] 100. McColl D, Margot N, Wulfsohn M, Coakley D, Cheng A, Miller M. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with TDF. J Acquir Immune Defic Syndr. 2004;37:1340–50. [PubMed] 101. Prado J, Franco S, Matamoros T, et al. Relative replication fitness of multi-nucleoside analog-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology. 2004;326:103–12. [PubMed] 102. Shirasaka T, Kavlick M, Ueno T, et al. Emergence of HIV-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92:2398–402. [PubMed] 103. Iversen A, Shafer R, Wehrly K, et al. Multidrug-resistant HIV-1 strains resulting from combination antiretroviral therapy. J Virol. 1996;70:1086–90. [PMC free article] [PubMed] 104. Shafer R, Iversen A, Winters M, Aguiniga E, Katzenstein D, Merigan T. Drug resistance and heterogeneous long-term virologic responses of HIV-1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis. 1995;172:70–8. [PubMed] 105. Kosalaraksa P, Kavlick M, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant HIV-1 in an In vitro competitive HIV-1 replication assay. J Virol. 1999;73:5356–63. [PMC free article] [PubMed] 106. Garcia-Lerma J, Gerrish P, Wright A, Qari S, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant HIV- 1. J Virol. 2000;74:9339–46. [PMC free article] [PubMed] 107. Dykes C, Demeter L. Clinical significance of HIV-1 replication fitness. Clin Microbiol Rev. 2007;20:550–78. [PMC free article] [PubMed] 108. Rodes B, Holguin A, Soriano V, et al. Emergence of drug resistance mutations in HIV-2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol. 2000;38:1370–4. [PMC free article] [PubMed] 109. Brandin E, Lindborg L, Gyllensten K, et al. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2003;19:543–50. [PubMed] 110. Gallego O, de Mendoza C, Labarga P, et al. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. HIV Clin Trials. 2003;4:372–81. [PubMed] 111. Zaccarelli M, Perno C, Forbici F, et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis. 2004;38:433–7. [PubMed] 112. Saracino A, Monno L, Scudeller L, et al. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and nonnucleoside inhibitors. J Med Virol. 2006;78:9–17. [PubMed] 113. Paolucci S, Baldanti F, Maga G, et al. Gln145Met/Leu changes in HIV-1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. Antimicrob Agents Chemother. 2004;48:4611–7. [PMC free article] [PubMed] 114. Paolucci S, Baldanti F, Tinelli M, Maga G, Gerna G. Detection of a new HIV-1 reverse transcriptase mutation (Q145M) conferring resistance to nucleoside and nonnucleoside inhibitors in a patient failing HAART. AIDS. 2003;17:924–7. [PubMed] 115. Smith R, Klarmann G, Stray K, et al. A new point mutation (P157S) in the reverse transcriptase of HIV-1 confers low-level resistance to (-)-beta2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1999;43:2077–80. [PMC free article] [PubMed] 116. Picard V, Angelini E, Maillard A, et al. Comparison of genotypic and phenotypic resistance patterns of HIV-1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J Infect Dis. 2001;184:781–4. [PubMed] 117. Nikolenko G, Palmer S, Maldarelli F, Mellors J, Coffin J, Pathak V. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNaseH activity and nucleotide excision. Proc Natl Acad Sci USA. 2005;102:2093–8. [PubMed] 118. Yap S, Sheen C, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007;4:e335. [PMC free article] [PubMed] 119. Kemp S, Shi C, Bloor S, Harrigan P, Mellors J, Larder B. A novel polymorphism at codon 333 of HIV-1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′,3′-dideoxy-3′-thiacytidine. J Virol. 1998;72:5093–8. [PMC free article] [PubMed] 120. Nikolenko G, Delviks-Frankenberry K, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc Natl Acad Sci USA. 2007;104:317–22. [PubMed] 121. Brehm J, Koontz D, Meteer J, Pathak V, Sluis-Cremer N, Mellors J. Selection of mutations in the connection and RNaseH domains of HIV-1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J Virol. 2007;81:7852–9. [PMC free article] [PubMed] 122. Zelina S, Sheen C, Radzio J, Mellors J, Sluis-Cremer N. Mechanisms by which the G333D mutation in HIV-1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob Agents Chemother. 2008;52:157–63. [PMC free article] [PubMed] 123. Delviks-Frankenberry K, Nikolenko G, Barr R, Pathak V. Mutations in HIV-1 RNaseH primer grip enhance 3′-azido-3′-deoxythymidine resistance. J Virol. 2007;81:6837–45. [PMC free article] [PubMed] 124. Roquebert B, Wirden M, Simon A, et al. Relationship between mutations in HIV-1 RNaseH domain and NRTI resistance mutations in naive and pretreated HIV infected patients. J Med Virol. 2007;79:207–11. [PubMed] 125. Ntemgwa M, Wainberg M, Oliveira M, et al. Variations in reverse transcriptase and RNaseH domain mutations in HIV-1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother. 2007;51:3861–9. [PMC free article] [PubMed] 126. Sarafianos S, Das K, Hughes S, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol. 2004;14:716–30. [PubMed] 127. Ren J, Stammers D. Structural basis for drug resistance mechanisms for nonnucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008;134:157–70. [PubMed] 128. Shulman N, Zolopa A, Passaro D, et al. Efavirenz-and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr. 2000;23:221–6. [PubMed] 129. Lecossier D, Shulman N, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr. 2005;38:37–42. [PubMed] 130. Huang W, Gamarnik A, Limoli K, Petropoulos C, Whitcomb J. Amino acid substitutions at position 190 of HIV-1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol. 2003;77:1512–23. [PMC free article] [PubMed] 131. Uhlmann E, Tebas P, Storch G, et al. Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. J Clin Virol. 2004;31:198–203. [PubMed] 132. Bacheler L, Jeffrey S, Hanna G, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing NNRTI therapy. J Virol. 2001;75:4999–5008. [PMC free article] [PubMed] 133. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773–82. [PMC free article] [PubMed] 134. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among NNRTI limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses. 2002;18:835–8. [PubMed] 135. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a NNRTI-containing regimen. J Med Virol. 2001;65:445–8. [PubMed] 136. Walmsley S, Kelly D, Tseng A, Humar A, Harrigan P. NNRTI failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. AIDS. 2001;15:1581–4. [PubMed] 137. Madruga J, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38. [PubMed] 138. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39–48. [PubMed]
139. Vingerhoets J, Buelens M, Peeters M, et al. Impact of baseline mutations on the virologic response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther. 2007;12:S34. abstract 32.
140. Pelemans H, Esnouf R, Dunkler A, et al. Characteristics of the Pro225His mutation in HIV-1 reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol. 1997;71:8195–203. [PMC free article] [PubMed] 141. Parkin N, Gupta S, Chappey C, Petropoulos C. The K101P and K103R/V179D mutations in HIV-1 reverse transcriptase confer resistance to NNRTI. Antimicrob Agents Chemother. 2006;50:351–4. [PMC free article] [PubMed] 142. Balzarini J, Pelemans H, Esnouf R, De Clercq E. A novel mutation (F227L) arises in the reverse transcriptase of HIV-1 on dose-escalating treatment of HIV type 1-infected cell cultures with the NNRTI thiocarboxanilide UC-781. AIDS Res Hum Retroviruses. 1998;14:255–60. [PubMed]
143. Huang W, Parkin N, Lie Y, et al. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antivir Ther. 2000;5(Suppl 3):2425.
144. Vingerhoets J, De Baere I, Azijin H, et al. Antiviral activity of TMC125 against a panel of site-directed mutants encompassing mutations observed in vitro and in vivo. 11th CROI; San Francisco. 2004. abstract 621.
145. Su G, Yan J, Li Y, et al. In vitro selection and characterization of viruses resistant to R1206 a novel NNRTI. Antivir Ther. 2007;12:S35. abstract 33.
146. Harrigan P, Salim M, Stammers DK, et al. A Mutation in the 3′ region of the HIV- 1 reverse transcriptase (Y318F) associated with NNRTI resistance. J Virol. 2002;76:6836–40. [PMC free article] [PubMed] 147. Rhee S, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. HIV reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298–303. [PMC free article] [PubMed] 148. Shafer R, Rhee S, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21:215–23. [PMC free article] [PubMed] 149. Harrigan P, Hertogs K, Verbiest W, et al. Modest decreases in NNRTI susceptibility do not influence virologic outcome in patients receiving initial NNRTI-containing triple therapy. Antivir Ther. 2003;8:395–402. [PubMed] 150. Bannister W, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and virologic response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008;22:367–76. [PubMed] 151. Brown A, Precious H, Whitcomb J, et al. Reduced susceptibility of HIV-1 from patients with primary HIV infection to NNRTI is associated with variation at novel amino acid sites. J Virol. 2000;74:10269–73. [PMC free article] [PubMed] 152. Ceccherini-Silberstein F, Svicher V, Sing T, et al. Characterization and structural analysis of novel mutations in HIV-1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol. 2007;81:11507–19. [PMC free article] [PubMed] 153. Kleim J, Rosner M, Winkler I, et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of HIV-1 reverse transcriptase on HIV-1 replication results in the emergence of NRTI-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA. 1996;93:34–8. [PubMed] 154. Koval C, Dykes C, Wang J, Demeter L. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology. 2006;353:184–92. [PubMed] 155. Gao Y, Paxinos E, Galovich J, et al. Characterization of a subtype D HIV-1 isolate that was obtained from an untreated individual and that is highly resistant NNRTI. J Virol. 2004;78:5390–401. [PMC free article] [PubMed] 156. Eshleman S, Jones D, Galovich J, et al. Phenotypic drug resistance patterns in subtype A HIV-1 clones with NNRTI resistance mutations. AIDS Res Hum Retroviruses. 2006;22:289–93. [PubMed] 157. Whitcomb J, Huang W, Limoli K, et al. Hypersusceptibility to NNRTI in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41–7. [PubMed] 158. Shulman N, Bosch R, Mellors J, Albrecht M, Katzenstein D. Genetic correlates of efavirenz hypersusceptibility. AIDS. 2004;18:1781–5. [PubMed] 159. Condra J, Holder D, Schleif W, et al. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor. J Virol. 1996;70:8270–6. [PMC free article] [PubMed] 160. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760–6. [PubMed] 161. Kempf D, Isaacson J, King M, et al. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462–9. [PMC free article] [PubMed] 162. Patick A, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV protease. Antimicrob Agents Chemother. 1996;40:292–7. [PMC free article] [PubMed] 163. Lawrence J, Schapiro J, Winters M, et al. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J Infect Dis. 1999;179:1356–64. [PubMed] 164. Walmsley S, Becker M, Zhang M, Humar A, Harrigan P. Predictors of virologic response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir. Antivir Ther. 2001;6:47–54. [PubMed] 165. Casado J, Dronda F, Hertogs K, et al. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. AIDS Res Hum Retroviruses. 2001;17:93–8. [PubMed] 166. Johnston E, Winters M, Rhee S, Merigan T, Schiffer C, Shafer R. Association of a novel HIV-1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother. 2004;48:4864–8. [PMC free article] [PubMed] 167. Winters B, Montaner J, Harrigan P, et al. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J Acquir Immune Defic Syndr. 2008;48:26–34. [PubMed] 168. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature ATV-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis. 2004;189:1802–10. [PubMed]
169. Coakley E, Mass M, Parkin N. Atazanavir resistance in a PI-naïve patient treated with atazanavir/ritonavir associated with development of high-level atazanavir resistance and the N88S mutation in protease. 12th CROI; Boston. 2005. abstract 716.
170. Vora S, Marcelin A, Gunthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS. 2006;20:35–40. [PubMed] 171. Pellegrin I, Breilh D, Ragnaud J, et al. Virologic responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study) Antivir Ther. 2006;11:421–9. [PubMed]
172. Coakley E, Chappey C, Maa J, et al. Evaluation of phenotypic clinical cutoff for atazanavir/ritonavir in patients who changed only the protease inhibitor component of HAART: A confirmatory week 2 analysis of AI424-045. 13th CROI; Denver. 2006. abstract 634.
173. Zolopa A, Towner W, Butcher D, Wang S, Maa J, Seekins D. Resistance profile after viral rebound on atazanavir-containing therapy: focus on protease inhibitor-naive subjects in the IMPACT study (BMS AI424-128) Antivir Ther. 2007;12:S86. abstract 77.
174. Winters B, Montaner J, Harrigan R, et al. Development of VircoTYPE HIV-1 resistance analysis including clinical cut-offs for ritonavir-boosted atazanavir and fosamprenavir. Antivir Ther. 2007;12:S170. abstract 155.
175. Zolopa A, Shafer R, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous PI therapy had failed. Ann Intern Med. 1999;131:813–21. [PMC free article] [PubMed] 176. Marcelin A, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in HIV-1 PI-experienced patients. Antimicrob Agents Chemother. 2004;48:4687–92. [PMC free article] [PubMed] 177. Marcelin A, Flandre P, de Mendoza C, et al. Clinical validation of saquinavir/ritonavir genotypic resistance score in PI-experienced patients. Antivir Ther. 2007;12:247. [PubMed] 178. Dandache S, Sevigny G, Yelle J, et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel PI of HIV-1. Antimicrob Agents Chemother. 2007;51:4036–43. [PMC free article] [PubMed]
179. Marcelin A, Flandre P, Molina J, et al. Genotypic analysis of the virologic response to fosamprenavir/ritonavir in clinical trials: CONTEXT and TRIAD. 14th CROI; Los Angeles. 2007. abstract 608.
180. Pellegrin I, Breilh D, Coureau G, et al. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother. 2007;51:1473–80. [PMC free article] [PubMed] 181. Masquelier B, Assoumou K, Descamps D, et al. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J Antimicrob Chemother. 2008;61:1362–8. [PubMed] 182. Friend J, Parkin N, Liegler T, Martin J, Deeks S. Isolated lopinavir resistance after virologic rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18:1965–6. [PubMed] 183. Kagan R, Shenderovich M, Heseltine P, Ramnarayan K. Structural analysis of an HIV-1 protease I47A mutant resistant to the PI lopinavir. Protein Sci. 2005;14:1870–8. [PubMed] 184. Baxter J, Schapiro J, Boucher CA, et al. Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the PI tipranavir. J Virol. 2006;80:10794–801. [PMC free article] [PubMed] 185. Mo H, Parkin N, Stewart K, et al. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to HIV PI and impair viral replication. Antimicrob Agents Chemother. 2007;51:732–5. [PMC free article] [PubMed]
186. Elston R, Scherer J, Hall D, et al. De-selection of the I50V mutation occurs in clinical isolates during aptivus/r (tipranavir/ritonavir)-based therapy. Antivir Ther. 2006;11:S102. abstract 92.
187. Ziermann R, Limoli K, Das K, Arnold E, Petropoulos C, Parkin N. A mutation in HIV-1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol. 2000;74:4414–9. [PMC free article] [PubMed]
188. Braun P, Walter H, Hoffman D, et al. Clinically relevant resensitization of PI saquinavir and atazanavir by L76V in multidrug-resistant HIV-1-infected patients. Antivir Ther. 2007;12:S142. abstract 129.
189. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in HIV-1: phenotypic analysis of protease and gag co-evolution in PI-treated patients. J Virol. 1998;72:7632–7. [PMC free article] [PubMed] 190. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13:2349–59. [PubMed] 191. Martinez-Picado J, Savara A, Sutton L, D'Aquila R. Replicative fitness of PI-resistant mutants of HIV-1. J Virol. 1999;73:3744–52. [PMC free article] [PubMed] 192. van Maarseveen N, de Jong D, Boucher C, Nijhuis M. An increase in viral replicative capacity drives the evolution of PI-resistant HIV-1 in the absence of drugs. J Acquir Immune Defic Syndr. 2006;42:162–8. [PubMed] 193. Hoffman N, Schiffer C, Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology. 2003;314:536–48. [PubMed] 194. Perno C, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of HIV and virologic failure in drug-naive patients treated with PI-based therapy. J Infect Dis. 2001;184:983–91. [PubMed] 195. Perno C, Cozzi-Lepri A, Forbici F, et al. J Infect Dis. Vol. 189. 2004. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first PI antiretroviral regimens failed; pp. 1983–7. [PubMed] 196. Wu T, Schiffer C, Gonzales M, et al. Mutation patterns and structural correlates in HIV-1 protease following different PI treatments. J Virol. 2003;77:4836–47. [PMC free article] [PubMed] 197. Parkin N, Chappey C, Petropoulos C. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS. 2003;17:955–61. [PubMed] 198. Ceccherini-Silberstein F, Erba F, Gago F, et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS. 2004;18:F11–9. [PubMed] 199. Svicher V, Ceccherini-Silberstein F, Erba F, et al. Novel HIV-1 protease mutations potentially involved in resistance to PI. Antimicrob Agents Chemother. 2005;49:2015–25. [PMC free article] [PubMed] 200. Scherer J, Boucher C, Baxter J, Schapiro J, Kohlbrenner V, Hall D. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score. 11th European AIDS Conference; Madrid, Spain. 2007. abstract P3.4/07. [PubMed] 201. De Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses. 2008;24:379–88. [PubMed]
202. De Meyer S, Dierynck I, Lathouwers E, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3, and DUET-1 and DUET-2. 6th European HIV Drug Resistance Workshop; Budapest, Hungary. 2008. abstract 54.
203. Cote H, Brumme Z, Harrigan P. HIV-1 protease cleavage site mutations associated with PI cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol. 2001;75:589–94. [PMC free article] [PubMed] 204. Dauber D, Ziermann R, Parkin N, et al. Altered substrate specificity of drug-resistant HIV-1 protease. J Virol. 2002;76:1359–68. [PMC free article] [PubMed] 205. Prabu-Jeyabalan M, Nalivaika E, King N, Schiffer C. Structural basis for co-evolution of a HIV-1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol. 2004;78:12446–54. [PMC free article] [PubMed] 206. Malet I, Roquebert B, Dalban C, et al. Association of Gag cleavage sites to protease mutations and to virologic response in HIV-1 treated patients. J Infect. 2007;54:367–74. [PubMed] 207. Pettit S, Lindquist J, Kaplan A, Swanstrom R. Processing sites in the HIV-1 Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. 2005;2:66. [PMC free article] [PubMed] 208. Zhang Y, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997;71:6662–70. [PMC free article] [PubMed] 209. Verheyen J, Litau E, Sing T, et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther. 2006;11:879–87. [PubMed] 210. Kolli M, Lastere S, Schiffer CA. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology. 2006;347:405–9. [PubMed] 211. Carrillo A, Stewart K, Sham H, et al. In vitro selection and characterization of HIV-1 variants with increased resistance to ABT-378, a novel. PI J Virol. 1998;72:7532–41. [PMC free article] [PubMed] 212. Maguire M, Guinea R, Griffin P, et al. Changes in HIV-1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol. 2002;76:7398–406. [PMC free article] [PubMed] 213. Bally F, Martinez R, Peters S, Sudre P, Telenti A. Polymorphism of HIV-1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to PI. AIDS Res Hum Retroviruses. 2000;16:1209–13. [PubMed] 214. Nijhuis M, van Maarseveen N, Lastere S, et al. A novel substrate-based HIV-1 PI drug resistance mechanism. PLoS Med. 2007;4:e36. [PMC free article] [PubMed] 215. Kaufmann G, Suzuki K, Cunningham P, et al. Impact of HIV-1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virologic response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses. 2001;17:487–97. [PubMed] 216. Gatanaga H, Suzuki Y, Tsang H, et al. J Biol Chem. Vol. 277. 2002. Amino acid substitutions in Gag protein at noncleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against PI; pp. 5952–61. [PubMed] 217. Brumme Z, Chan K, Dong W, et al. Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating ART. Antivir Ther. 2003;8:91–6. [PubMed] 218. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in PI-resistant HIV-1. Antimicrob Agents Chemother. 2004;48:444–52. [PMC free article] [PubMed] 219. Lastere S, Dalban C, Collin G, et al. Impact of insertions in the HIV-1 p6 PTAPP region on the virologic response to amprenavir. Antivir Ther. 2004;9:221–7. [PubMed] 220. Parkin N, Schapiro J. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther. 2004;9:3–12. [PubMed] 221. Rhee S, Kantor R, Katzenstein D, et al. HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS. 2006;20:643–51. [PMC free article] [PubMed] 222. Velazquez-Campoy A, Todd M, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA. 2001;98:6062–7. [PubMed] 223. Holguin A, Paxinos E, Hertogs K, Womac C, Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to PI in HIV-1 non-B subtypes. J Clin Virol. 2004;31:215–20. [PubMed] 224. Sanches M, Krauchenco S, Martins N, Gustchina A, Wlodawer A, Polikarpov I. Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development. J Mol Biol. 2007;369:1029–40. [PubMed] 225. Geretti A. HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis. 2006;19:1–7. [PubMed] 226. Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112. [PMC free article] [PubMed] 227. Cane P, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. Resistance-associated mutations in the HIV-1 subtype c protease gene from treated and untreated patients in the UK. J Clin Microbiol. 2001;39:2652–4. [PMC free article] [PubMed] 228. Sugiura W, Matsuda Z, Yokomaku Y, et al. Interference between D30N and L90M in selection and development of PI-resistant HIV-1. Antimicrob Agents Chemother. 2002;46:708–15. [PMC free article] [PubMed] 229. Grossman Z, Paxinos E, Averbuch D, et al. Mutation D30N is not preferentially selected by HIV-1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother. 2004;48:2159–65. [PMC free article] [PubMed] 230. Abecasis A, Deforche K, Snoeck J, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS. 2005;19:1799–806. [PubMed] 231. Calazans A, Brindeiro R, Brindeiro P, et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to PI is caused by the L89M polymorphism. J Infect Dis. 2005;191:1961–70. [PubMed] 232. Gonzalez L, Brindeiro R, Aguiar R, et al. Antimicrob Agents Chemother. Vol. 48. 2004. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of HIV-1 with subtype B and C proteases; pp. 3552–5. [PMC free article] [PubMed] 233. Deforche K, Silander T, Camacho R, et al. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics. 2006;22:2975–9. [PubMed]
234. Camacho R, Godinho A, Gomes P, et al. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutations. Antivir Ther. 2005;10:S151. abstract 138.
235. van de Vijver D, Wensing A, Angarano G, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr. 2006;41:352–60. [PubMed] 236. van Gent D, Groeneger A, Plasterk R. Mutational analysis of the integrase protein of HIV- 2. Proc Natl Acad Sci USA. 1992;89:9598–602. [PubMed] 237. Pommier Y, Johnson A, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4:236–48. [PubMed] 238. Chen J, Krucinski J, Miercke L, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA. 2000;97:8233–8. [PubMed] 239. Wang J, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. Embo J. 2001;20:7333–43. [PubMed] 240. Goldgur Y, Craigie R, Cohen G, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA. 1999;96:13040–3. [PubMed] 241. Fikkert V, Hombrouck A, Van Remoortel B, et al. Multiple mutations in HIV-1 integrase confer resistance to the clinical trial drug S-1360. AIDS. 2004;18:2019–28. [PubMed] 242. Hazuda D, Anthony N, Gomez R, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA. 2004;101:11233–8. [PubMed] 243. Sotriffer C, Ni H, McCammon J. Active site binding modes of HIV-1 integrase inhibitors. J Med Chem. 2000;43:4109–17. [PubMed] 244. Savarino A. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology. 2007;4:21. [PMC free article] [PubMed] 245. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of a novel HIV integrase inhibitor, elvitegravir (JTK303/GS-9137) J Virol. 2008;82:764–74. [PMC free article] [PubMed]
246. Suzuki H, Fujino M, Matsuda M, Yen H, Iwatani Y, Sugiura W. Effects of protease and reverse transcriptase inhibitor-resistance mutations on integrase polymorphisms in multidrug resistance cases. Antiviral Ther. 2007;12:S4. abstract 2.
247. Myers R, Pillay D. HIV-1 integrase sequence variation and covariation. Antiviral Ther. 2007;12:S5. abstract 3.
248. Ceccherini-Silberstein F, Malet I, Fabeni L, et al. Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients. Antivir Ther. 2007;12:S6. abstract 4.
249. Lataillade M, Chiarella J, Kozal M. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther. 2007;12:563–70. [PubMed]
250. Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th CROI; Los Angeles. 2007. abstract 627.
251. Hazuda D, Miller M, Nguyen B, Zhao J. Resistance to the HIV integrase inhibitor raltegravir: analysis of protocol 005, a phase II study in patients with triple-class resistant HIV-1. Antivir Ther. 2007;12 abstract 8.
252. Mccoll D, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvitegravir (GS-9137) Antivir Ther. 2007;12 abstract 9.
253. Ren C, May S, Miletti T, Bedard J. In vitro cross-resistance studies of five different classes of integrase inhibitors in recombinant HIV-1. Antivir Ther. 2007;12:S3. abstract 1.
254. Hombrouck A, Voet A, Van Remoortel B, et al. Mutations in HIV-1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother. 2008;52:2069–78. [PMC free article] [PubMed] 255. Rowley M. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem. 2008;46:1–28. [PubMed]
256. Merck. Isentress. Package Insert 2007.
257. Malet I, Delelis O, Valantin M, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351–8. [PMC free article] [PubMed] 258. Cabrera C, Marfil S, Garcia E, et al. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS. 2006;20:2075–80. [PubMed] 259. Lu J, Deeks S, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006;43:60–4. [PubMed] 260. Hanna S, Yang C, Owen S, Lal R. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [corrected] AIDS. 2002;16:1603–8. [PubMed] 261. Xu L, Hue S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS. 2002;16:1684–6. [PubMed] 262. Villahermosa M, Perez-Alvarez L, Carmona R, et al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS. 2003;17:1083–6. [PubMed] 263. Cilliers T, Patience T, Pillay C, Papathanasopoulos M, Morris L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004;20:477–82. [PubMed] 264. Aghokeng A, Ewane L, Awazi B, et al. Enfuvirtide binding domain is highly conserved in non-B HIV-1 strains from Cameroon, West Central Africa. AIDS Res Hum Retroviruses. 2005;21:430–3. [PubMed] 265. Holguin A, Faudon J, Labernardiere J, Soriano V. Susceptibility of HIV-1 non-B subtypes and recombinant variants to enfuvirtide. J Clin Virol. 2007;38:176–80. [PubMed] 266. Labrosse B, Labernardiere J, Dam E, et al. Baseline susceptibility of primary HIV-1 to entry inhibitors. J Virol. 2003;77:1610–3. [PMC free article] [PubMed]
267. Sista P, Melby T, Greenberg M, et al. Subgroup analysis of baseline susceptibility and early virologic response to enfuvirtide in the combined TORO studies. Antivir Ther. 2003;8:S60.
268. Reeves J, Gallo S, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002;99:16249–54. [PubMed] 269. Melby T, Sista P, DeMasi R, et al. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses. 2006;22:375–85. [PubMed] 270. Sista P, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS. 2004;18:1787–94. [PubMed] 271. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of HIV-1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother. 2004;48:3253–9. [PMC free article] [PubMed] 272. Marcelin A, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viremia under T-20. AIDS. 2004;18:1340–2. [PubMed] 273. Mink M, Mosier S, Janumpalli S, et al. Impact of HIV-1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. 2005;79:12447–54. [PMC free article] [PubMed] 274. Su C, Melby T, DeMasi R, Ravindran P, Heilek-Snyder G. Genotypic changes in HIV-1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. J Clin Virol. 2006;36:249–57. [PubMed] 275. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother. 2005;49:1113–9. [PMC free article] [PubMed] 276. Baldwin C, Sanders R, Deng Y, et al. Emergence of a drug-dependent HIV-1 variant during therapy with the T20 fusion inhibitor. J Virol. 2004;78:12428–37. [PMC free article] [PubMed] 277. Tolstrup M, Selzer-Plon J, Laursen A, et al. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K) AIDS. 2007;21:519–21. [PubMed] 278. Cilliers T, Moore P, Coetzer M, Morris L. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005;21:776–83. [PubMed] 279. D'Arrigo R, Ciccozzi M, Gori C, et al. gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure. AIDS Res Hum Retroviruses. 2007;23:1296–302. [PubMed] 280. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes D. Relative replicative fitness of HIV-1 mutants resistant to enfuvirtide (T-20) J Virol. 2004;78:4628–37. [PMC free article] [PubMed] 281. Deeks S, Lu J, Hoh R, et al. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis. 2007;195:387–91. [PubMed] 282. Aquaro S, D'Arrigo R, Svicher V, et al. Specific mutations in HIV-1 gp41 are associated with immunologic success in HIV-1-infected patients receiving enfuvirtide treatment. J Antimicrob Chemother. 2006;58:714–22. [PubMed] 283. Reeves J, Lee F, Miamidian J, Jabara C, Juntilla M, Doms R. Enfuvirtide resistance mutations: impact on HIV envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol. 2005;79:4991–9. [PMC free article] [PubMed] 284. Hartley O, Klasse P, Sattentau Q, Moore J. V3: HIV's switch hitter. AIDS Res Hum Retroviruses. 2005;21:171–89. [PubMed] 285. Dragic T, Trkola A, Thompson D, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA. 2000;97:5639–44. [PubMed] 286. Castonguay L, Weng Y, Adolfsen W, et al. Binding of 2-aryl-4-(piperidin-1yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry. 2003;42:1544–50. [PubMed] 287. Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit HIV-1 entry. J Virol. 2003;77:5201–8. [PMC free article] [PubMed] 288. Westby M, van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother. 2005;16:339–54. [PubMed] 289. Maeda K, Das D, Ogata-Aoki H, et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem. 2006;281:12688–98. [PubMed] 290. Seibert C, Ying W, Gavrilov S, et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology. 2006;349:41–54. [PubMed] 291. Lobritz M, Marozsan A, Troyer R, Arts E. Natural variation in the V3 crown of HIV-1 affects replicative fitness and entry inhibitor sensitivity. J Virol. 2007;81:8258–69. [PMC free article] [PubMed] 292. Pugach P, Marozsan A, Ketas T, Landes E, Moore J, Kuhmann S. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology. 2007;361:212–28. [PMC free article] [PubMed] 293. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV-1 activity. Antimicrob Agents Chemother. 2005;49:4721–32. [PMC free article] [PubMed] 294. Strizki J, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against HIV-1. Antimicrob Agents Chemother. 2005;49:4911–19. [PMC free article] [PubMed] 295. Trkola A, Kuhmann S, Strizki J, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA. 2002;99:395–400. [PubMed] 296. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 HIV-1 in vitro. J Virol. 2004;78:8654–62. [PMC free article] [PubMed] 297. Marozsan A, Kuhmann S, Morgan T, et al. Generation and properties of a HIV-1 isolate resistant to the small molecule CCR5 inhibitor, SCH417690 (SCH-D) Virology. 2005;338:182–99. [PubMed] 298. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359–71. [PMC free article] [PubMed] 299. Kuhmann S, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of HIV-1 escape from a small-molecule CCR5 inhibitor. J Virol. 2004;78:2790–807. [PMC free article] [PubMed] 300. Rusert P, Kuster H, Joos B, et al. Virus isolates during acute and chronic HIV-1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol. 2005;79:8454–69. [PMC free article] [PubMed] 301. Baba M, Miyake H, Wang X, Okamoto M, Takashima K. Isolation and characterization of HIV-1 resistant to the small-molecule CCR5 antagonist TAK 652. Antimicrob Agents Chemother. 2007;51:707–15. [PMC free article] [PubMed] 302. Ogert R, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology. 2008;373:387–99. [PubMed]
303. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and 2. Antivir Ther. 2007;12:S12. abstract 10.
304. Tsibris A, Gulick R, Su Z, et al. In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc: findings from ACTG 5211. Antivir Ther. 2007;12:S15. abstract 13.
305. Moore J, Kitchen S, Pugach P, Zack J. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of HIV-1 infection. AIDS Res Hum Retroviruses. 2004;20:111–26. [PubMed] 306. Brumme Z, Goodrich J, Mayer H, et al. Molecular and clinical epidemiology of CXCR4 using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466–74. [PubMed] 307. Hunt P, Harrigan P, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis. 2006;194:926–30. [PubMed] 308. Poveda E, Briz V, Quinones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS. 2006;20:1359–67. [PubMed] 309. Melby T, Despirito M, Demasi R, Heilek-Snyder G, Greenberg M, Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis. 2006;194:238–46. [PubMed] 310. Wilkin T, Su Z, Kuritzkes D, et al. HIV-1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591–5. [PubMed] 311. Whitcomb J, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV-1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566–75. [PMC free article] [PubMed] 312. Huang W, Eshleman S, Toma J, et al. Coreceptor tropism in HIV-1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol. 2007;81:7885–93. [PMC free article] [PubMed] 313. Pastore C, Nedellec R, Ramos A, et al. Conserved changes in envelope function during HIV-1 coreceptor switching. J Virol. 2007;81:8165–79. [PMC free article] [PubMed] 314. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier D. HIV-1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol. 2006;80:750–8. [PMC free article] [PubMed] 315. Pastore C, Ramos A, Mosier D. Intrinsic obstacles to HIV-1 coreceptor switching. J Virol. 2004;78:7565–74. [PMC free article] [PubMed] 316. Jensen M, van 't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 2003;5:104–12. [PubMed] 317. Sander O, Sing T, Sommer I, et al. Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol. 2007;3:e58. [PMC free article] [PubMed] 318. Sing T, Low A, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther. 2007;12:1097–106. [PubMed] 319. Huang W, Toma J, Fransen S, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of HIV-1 env protein. J Virol. 2008;82:5584–93. [PMC free article] [PubMed] 320. Moncunill G, Armand-Ugon M, Pauls E, Clotet B, Este J. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS. 2008;22:23–31. [PubMed]
321. Reeves J, Han D, Wilkin T, et al. An enhanced version of the Trofile HIV coreceptor tropism assay predicts emergence of CXCR4 use in ACTG5211 vicriviroc trial samples; 15th CROI; 2008. abstract 869.
322. Fatkenheuer G, Pozniak A, Johnson M, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170–2. [PubMed] 323. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using HIV-1 variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909–20. [PMC free article] [PubMed]
324. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antviral Ther. 2007;12:S65. abstract 56.
325. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS. 2007;21:1293–9. [PubMed]
326. Kitrinos K, Irlbeck D, LaBranche C, Madsen H, Demarest J. Virologic characterization of treatment naive subjects failing an aplaviroc-based regimen with either lamivudine/zidovudine or lopinavir/ritonavir. Antivir Ther. 2006;11:S26. abstract 21.
327. Low A, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F17–24. [PubMed] 328. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007;17:1195–201. [PubMed]
329. Tsibris A, Arnaout R, Lo C, et al. V3 loop sequence dynamics in subjects failing CCR5 antagonist therapy. Keystone Symposium on HIV Pathogenesis; Banff, Alberta, Canada. 2008.